The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2021 | Phase II CodeBreak 100 trial of sotorasib in advanced NSCLC
Outcomes in patients with heavily pre-treated advanced non-small cell lung cancer (NSCLC) are very poor. To address this, the Phase II CodeBreak 100 trial (NCT03600883) investigated sotorasib, a first-in-class irreversible inhibitor of KRAS-G12C, in advanced or metastatic KRAS p.G12C-mutant NSCLC. Vamsidhar Velcheti, MD, New York University, NY, discusses the findings of the trial. After a median follow-up of 9.3 months, sotorasib showed a promising safety profile and led to deep and durable responses, with an overall response rate of over 37%. Around 13% of lung carcinomas harbor a KRAS-G12C mutation, and the trial results suggest sotorasib has the potential to be the first targeted treatment option for this patient population. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.
